Mode
Text Size
Log in / Sign up
N/A N=40 Randomized Quadruple-blind Treatment

An Evaluation of Low Level Laser Light Therapy for Autistic Disorder

Autistic Disorder

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
May 2021
Primary outcome: Primary: Mean Change From Baseline to Study Endpoint in the Aberrant Behavior Checklist (ABC) Irritability & Agitation Subscale Score. — -14.81; 0.37 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Erchonia HLS Laser (Device); Placebo Laser (Device)
Age
Pediatric · 5+ yrs
Sex
All
Sponsor
Erchonia Corporation
Primary completion
Oct 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Change From Baseline to Study Endpoint in the Aberrant Behavior Checklist (ABC) Irritability & Agitation Subscale Score.
-14.81; 0.37

Summary

The purpose of this study is to determine whether the Erchonia HLS Laser is effective in the treatment of irritability associated with autistic disorder in children and adolescents aged five (5) to seventeen (17) years.

Eligibility Criteria

Inclusion Criteria

  • Male or female child or adolescent aged 5 to 17 years
  • Meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision criteria (DSM-IV-TR) for autistic disorder within the past 2 years, as diagnosed by a trained, qualified medical professional such as a pediatric neurologist, child psychiatrist or developmental pediatrician
  • Diagnosis is confirmed by Autism Diagnostic Interview (ADI-R)
  • Demonstrates 'irritable' behaviors such as tantrums, aggression, self-injurious behavior, or a combination of such behaviors
  • Aberrant Behavior Checklist (ABC) Irritability Subscale score is >=18
  • Clinical Global Impressions - Severity (CGI-S) scale score is >=4 (moderately ill)
  • Current therapeutic/intervention plan for treating autistic disorder has been consistent/ stable over at least the past 3 months
  • Caregiver agrees, and it is possible for, the subject to abstain from partaking in new treatments to treat autistic disorder symptoms during the course of study participation
  • Female subjects of child-bearing age are willing and able to use acceptable means of contraception throughout study participation.

Exclusion Criteria

  • Primary or concurrent diagnosis of another disorder or other identifiable genetic condition associated with the autism spectrum scale or with mental retardation, including:

Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS); Asperger's Disorder; Rett's Disorder; Fragile-X Syndrome; Childhood Disintegrative Disorder; Down Syndrome

  • Seizure disorders (active), cerebrovascular disease or brain trauma as etiology of autistic behavior
  • Current diagnosis of, and treatment for, bipolar disorder, psychosis, schizophrenia, or major depression
  • Current use of a psychotropic drug deemed effective for the treatment of aggression, tantrums or self-injurious behavior
  • Known neurological disease, such as encephalitis
  • Significant sensory or motor impairment such as cerebral palsy
  • Diagnosis of epilepsy that is currently treated with anti-convulsant medication
  • Previous significant head trauma
  • Hearing loss requiring use of assistive devices such as hearing aids or cochlear implant
  • Significant visual impairment that cannot be adequately corrected with lenses
  • Documented mental age younger than 18 months
  • HIV and other autoimmune disorders
  • Active cancer or treatment for cancer within last 6 months
  • Unstable cardiac disease, such as a recent cardiac arrhythmias (including atrial fibrillation, ventricular fibrillation and irregular atrial-ventricular conduction time), or recent congestive heart failure, or recent myocardial infarction
  • Previous surgical interventions to the head/neck area
  • Sensitivity to, or contraindication for, light therapy
  • Subject is presently pregnant or breast feeding
  • Participation in a research study within the past 30 days
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03379662). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search